Clinical Trial Update: Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery [Phase 4]

View source ↗

Summary

Phase 4 mechanistic study assessing saxagliptin in patients with type 2 diabetes undergoing coronary artery bypass graft surgery. The trial was terminated and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Saxagliptin (Onglyza) (saxagliptin)

Snippet

Sponsor: Duke University | Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease | Phase 4 | Status: TERMINATED | Results posted: 2015-05-08